Bioresorbable scaffolds: a new paradigm in percutaneous coronary intervention.

Erhan Tenekecioglu, Vasim Farooq, Christos V Bourantas, Rafael Cavalcante Silva, Yoshinobu Onuma, Mustafa Yılmaz, Patrick W Serruys

Journal: BMC cardiovascular disorders 2016;16():38

PMID: 26868826

Abstract

Numerous advances and innovative therapies have been introduced in interventional cardiology over the recent years, since the first introduction of balloon angioplasty, but bioresorbable scaffold is certainly one of the most exciting and attracting one. Despite the fact that the metallic drug-eluting stents have significantly diminished the re-stenosis ratio, they have considerable limitations including the hypersensitivity reaction to the polymer that can cause local inflammation, the risk of neo-atherosclerotic lesion formation which can lead to late stent failure as well as the fact that they may preclude surgical revascularization and distort vessel physiology. Bioresorbable scaffolds overcome these limitations as they have the ability to dissolve after providing temporary scaffolding which safeguards vessel patency. In this article we review the recent developments in the field and provide an overview of the devices and the evidence that support their efficacy in the treatment of CAD. Currently 3 devices are CE marked and in clinical use. Additional 24 companies are developing these kind of coronary devices. Most frequently used material is PLLA followed by magnesium.

Address: ThoraxCentre, Erasmus Medical Centre, Rotterdam, The Netherlands. [email protected].; Manchester Heart Centre, Manchester Royal Infirmary, Central Manchester University, Hospitals NHS Trust, Manchester, UK. [email protected].; Institute of Cardiovascular Sciences, Manchester Academic Health Sciences Centre, University of Manchester, Manchester, UK. [email protected].; Institute of Cardiovascular Sciences, University College of London, London, UK. [email protected].; Department of Cardiology, Barts Health NHS Trust, London, UK. [email protected].; ThoraxCentre, Erasmus Medical Centre, Rotterdam, The Netherlands. [email protected].; ThoraxCentre, Erasmus Medical Centre, Rotterdam, The Netherlands. [email protected].; Department of Cardiology, Bursa Postgraduate Education and Research Hospital, Bursa, Turkey. [email protected].; ThoraxCentre, Erasmus Medical Centre, Rotterdam, The Netherlands. [email protected].; International Centre for Circulatory Health, Imperial College, London, UK. [email protected].; Interventional Cardiology Department, Erasmus MC, 's-Gravendijkwal 230, Rotterdam, 3015 CE, The Netherlands. [email protected].
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.